Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1974 1
1975 3
1976 1
1978 2
1979 2
1980 2
1981 2
1982 1
1983 4
1984 6
1985 1
1986 2
1987 3
1988 2
1989 7
1990 4
1991 1
1992 3
1993 6
1994 9
1995 8
1996 3
1997 11
1998 4
1999 10
2000 9
2001 13
2002 14
2003 15
2004 17
2005 33
2006 18
2007 27
2008 29
2009 44
2010 43
2011 34
2012 48
2013 57
2014 83
2015 85
2016 66
2017 78
2018 92
2019 88
2020 94
2021 103
2022 63
2023 69
2024 24

Text availability

Article attribute

Article type

Publication date

Search Results

1,192 results

Results by year

Filters applied: . Clear all
Page 1
Biomedical applications of Aloe vera.
Gao Y, Kuok KI, Jin Y, Wang R. Gao Y, et al. Crit Rev Food Sci Nutr. 2019;59(sup1):S244-S256. doi: 10.1080/10408398.2018.1496320. Epub 2018 Sep 13. Crit Rev Food Sci Nutr. 2019. PMID: 29999415 Review.
Over the last centuries, Aloe vera, a plant species belonging to the genus Aloe, have been extensively studied for various therapeutic activities, including anti-bacterial, anti-viral, anti-cancer activity, as well as immunoregulative and hepatoprotective properties, altho …
Over the last centuries, Aloe vera, a plant species belonging to the genus Aloe, have been extensively studied for various therapeuti …
Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial.
Barbui T, Vannucchi AM, De Stefano V, Masciulli A, Carobbio A, Ferrari A, Ghirardi A, Rossi E, Ciceri F, Bonifacio M, Iurlo A, Palandri F, Benevolo G, Pane F, Ricco A, Carli G, Caramella M, Rapezzi D, Musolino C, Siragusa S, Rumi E, Patriarca A, Cascavilla N, Mora B, Cacciola E, Mannarelli C, Loscocco GG, Guglielmelli P, Betti S, Lunghi F, Scaffidi L, Bucelli C, Vianelli N, Bellini M, Finazzi MC, Tognoni G, Rambaldi A. Barbui T, et al. Lancet Haematol. 2021 Mar;8(3):e175-e184. doi: 10.1016/S2352-3026(20)30373-2. Epub 2021 Jan 18. Lancet Haematol. 2021. PMID: 33476571 Clinical Trial.
The study involved 21 haematological centres across Italy. Participants were recruited in a consecutive order. Participants enrolled in the study were patients, aged 18-60 years, with a diagnosis of polycythaemia vera according to 2008-16 WHO criteria. ...INTERPRETA …
The study involved 21 haematological centres across Italy. Participants were recruited in a consecutive order. Participants enrolled …
Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms.
Vainchenker W, Kralovics R. Vainchenker W, et al. Blood. 2017 Feb 9;129(6):667-679. doi: 10.1182/blood-2016-10-695940. Epub 2016 Dec 27. Blood. 2017. PMID: 28028029 Free article. Review.
The most frequent mutation, JAK2V617F, activates the 3 main myeloid cytokine receptors (erythropoietin receptor, granulocyte colony-stimulating factor receptor, and MPL) whereas CALR or MPL mutants are restricted to MPL activation. This explains why JAK2V617F is associated with p …
The most frequent mutation, JAK2V617F, activates the 3 main myeloid cytokine receptors (erythropoietin receptor, granulocyte colony-stimulat …
JAK2 unmutated erythrocytosis: 2023 Update on diagnosis and management.
Gangat N, Szuber N, Tefferi A. Gangat N, et al. Am J Hematol. 2023 Jun;98(6):965-981. doi: 10.1002/ajh.26920. Epub 2023 Apr 3. Am J Hematol. 2023. PMID: 36966432
DISEASE OVERVIEW: JAK2 unmutated or non-polycythemia vera (PV) erythrocytosis encompasses a heterogenous spectrum of hereditary and acquired entities. ...Initial assessment should also include gathering of previous records on hematocrit (Hct) and hemoglobin (Hgb) levels, i …
DISEASE OVERVIEW: JAK2 unmutated or non-polycythemia vera (PV) erythrocytosis encompasses a heterogenous spectrum of hereditary and a …
Polycythaemia vera: molecular genetics, diagnostics and therapeutics.
Putter JS, Seghatchian J. Putter JS, et al. Vox Sang. 2021 Jul;116(6):617-627. doi: 10.1111/vox.13069. Epub 2021 Feb 26. Vox Sang. 2021. PMID: 33634867 Review.
Polycythaemia vera is one of several classical myeloproliferative neoplasms that may occur in a juvenile onset or late-onset adult forms. ...Concepts of genetics and immunology help define the origin and behaviour of the disease: the tracking of allele burdens of mutations …
Polycythaemia vera is one of several classical myeloproliferative neoplasms that may occur in a juvenile onset or late-onset adult fo …
The use of aloe vera in cancer radiation: An updated comprehensive review.
Farrugia CE, Burke ES, Haley ME, Bedi KT, Gandhi MA. Farrugia CE, et al. Complement Ther Clin Pract. 2019 May;35:126-130. doi: 10.1016/j.ctcp.2019.01.013. Epub 2019 Jan 31. Complement Ther Clin Pract. 2019. PMID: 31003648 Review.
Multiple controlled trials have been performed in order to evaluate the efficacy of aloe vera for the prevention and treatment of radiation side effects. Previous systematic reviews have examined the use of aloe vera for radiation-induced skin reactions, howe …
Multiple controlled trials have been performed in order to evaluate the efficacy of aloe vera for the prevention and treatment …
Polycythemia Vera (PV): Update on Emerging Treatment Options.
Benevolo G, Vassallo F, Urbino I, Giai V. Benevolo G, et al. Ther Clin Risk Manag. 2021 Mar 16;17:209-221. doi: 10.2147/TCRM.S213020. eCollection 2021. Ther Clin Risk Manag. 2021. PMID: 33758507 Free PMC article. Review.
Polycythemia Vera (PV) is a chronic myeloproliferative neoplasm characterized by exuberant red cell production leading to a broad range of symptoms that compromise quality of life and productivity of patients. ...High-risk patients (age >60 years and/or prior history of …
Polycythemia Vera (PV) is a chronic myeloproliferative neoplasm characterized by exuberant red cell production leading to a broad ran …
Erythrocytosis and CKD.
Aoun M, Jadoul M, Anders HJ. Aoun M, et al. Am J Kidney Dis. 2024 Apr 13:S0272-6386(24)00715-7. doi: 10.1053/j.ajkd.2024.02.015. Online ahead of print. Am J Kidney Dis. 2024. PMID: 38621632 Review.
Unlike anemia that is very common in chronic kidney disease (CKD) patients, erythrocytosis is less frequent but requires specific understanding by healthcare professionals in order to provide the best care. Erythrocytosis, especially when undiagnosed and untreated, can lea …
Unlike anemia that is very common in chronic kidney disease (CKD) patients, erythrocytosis is less frequent but requires specific understand …
Low-risk polycythemia vera and essential thrombocythemia: management considerations and future directions.
Goulart H, Mascarenhas J, Tremblay D. Goulart H, et al. Ann Hematol. 2022 May;101(5):935-951. doi: 10.1007/s00277-022-04826-7. Epub 2022 Mar 28. Ann Hematol. 2022. PMID: 35344066 Review.
Thrombotic events are a distinctive feature of the myeloproliferative neoplasms (MPNs) polycythemia vera (PV) and essential thrombocythemia (ET). Patients with these MPNs may also experience a poor quality of life secondary to symptom burden, as well as progression of dise …
Thrombotic events are a distinctive feature of the myeloproliferative neoplasms (MPNs) polycythemia vera (PV) and essential thrombocy …
[JAK2 inhibitors].
Hernández Boluda JC, Gómez M, Pérez A. Hernández Boluda JC, et al. Med Clin (Barc). 2016 Jul 15;147(2):70-5. doi: 10.1016/j.medcli.2016.02.014. Epub 2016 Mar 28. Med Clin (Barc). 2016. PMID: 27033437 Review. Spanish.
At present, there are several clinical trials evaluating the combination of ruxolitinib with other drugs, in order to improve its therapeutic activity as well as reducing haematologic toxicity....
At present, there are several clinical trials evaluating the combination of ruxolitinib with other drugs, in order to improve its the …
1,192 results